BRAIN. Broad Research in Artificial Intelligence and Neuroscience
e-ISSN: 2067-3957 | p-ISSN: 2068-0473
Covered in: Web of Science (ESCI); EBSCO; JERIH PLUS (hkdir.no); IndexCopernicus; Google Scholar; SHERPA/RoMEO; ArticleReach Direct; WorldCat; CrossRef; Peeref; Bridge of Knowledge (mostwiedzy.pl); abcdindex.com; Editage; Ingenta Connect Publication; OALib; scite.ai; Scholar9; Scientific and Technical Information Portal; FID Move; ADVANCED SCIENCES INDEX (European Science Evaluation Center, neredataltics.org); ivySCI; exaly.com; Journal Selector Tool (letpub.com); Citefactor.org; fatcat!; ZDB catalogue; Catalogue SUDOC (abes.fr); OpenAlex; Wikidata; The ISSN Portal; Socolar; KVK-Volltitel (kit.edu)
2025, Volume 16, Issue 2, pages: 186-212.
Submitted: February 17th, 2025 | *Accepted for publication:* May 1st, 2025

Breaking the Cycle: Addressing the Interplay Between Respiratory, Metabolic, and Psychiatric Disorders

Diana Patraș
Saint Apostle Andrew Emergency County Clinical Hospital, 177 Brailei St., 800578 Galati, Romania.
Univ Galati, Doctoral School Biomedicine Science, Galati, 800008, Romania.
patras.diana@yahoo.com

Anamaria Ciubară
Faculty of Medicine and Pharmacy, Dunarea de Jos University of Galati, 35 AI Cuza St., 800010 Galati, Romania.
anamburlea@yahoo.com
https://orcid.org/0000-0003-0740-3702

Alexandru Bogdan Ciubară
Univ Galati, Doctoral School Biomedicine Science, Galati, 800008, Romania.
bogdan.ciubara@ugal.ro
https://orcid.org/0000-0002-8037-6002

Lucreția Anghel
Saint Apostle Andrew Emergency County Clinical Hospital, 177 Brailei St., 800578 Galati, Romania;
Faculty of Medicine and Pharmacy, Dunarea de Jos University of Galati, 35 AI Cuza St., 800010 Galati, Romania.
anghel_lucretia@yahoo.com
https://orcid.org/0000-0002-9477-6760

Abstract: *Psychiatric disorders, chronic obstructive pulmonary disease (COPD), and type 2 diabetes (T2D) share common mechanisms, including neuroinflammation, oxidative stress, systemic inflammation, and gut microbiota alterations. This literature review evaluates key molecular and clinical intersections across these diseases. Analyzing peer-reviewed studies (2020–2025) from databases like PubMed and Scopus, our findings highlight oxidative stress and systemic inflammation as major drivers of disease progression, with hypoxia-induced neuroinflammation and gut dysbiosis emerging as critical factors. Early psychiatric screening in COPD and T2D patients is essential, alongside precision medicine approaches such as biomarker diagnostics and microbiome-based therapies. Addressing inflammation and autonomic dysfunction could help break the cycle of disease progression. This study advocates for a multidisciplinary healthcare approach, emphasising integrated, patient-centered management strategies.*

Keywords: *psychiatric disorders; COPD; type 2 diabetes; systemic inflammation; interdisciplinary healthcare.*

How to cite: Patraș, D., Ciubară, A., Ciubară, A. B. & Anghel, L. (2025). Breaking the cycle: addressing the interplay between respiratory, metabolic, and psychiatric disorders. *BRAIN. Broad Research in Artificial Intelligence and Neuroscience*, *16*(2), 186-212. https://doi.org/10.70594/brain/16.2/15

1. Introduction

The relationship between mental health, respiratory diseases, and metabolic disorders has been increasingly acknowledged as a crucial factor influencing patient outcomes. COPD and T2D can co-occur with psychological disorders, including depression and anxiety, resulting in a detrimental cycle of deteriorating physical and mental health (Rahi et al., 2023).

The incidence of depression and anxiety is notably elevated in patients with COPD and T2D, frequently resulting in diminished treatment adherence, worse quality of life, and increased mortality rates (Volpato et al., 2021).

Numerous studies have indicated that persons with COPD have a markedly elevated risk of mental health disorders attributable to the chronic stress associated with disease management, decreased oxygen levels, and neurochemical imbalances produced by inflammation (Moretta et al., 2024). Likewise, T2D has been associated with alterations in cerebral function, heightening vulnerability to mood problems. These problems are interrelated, exacerbating each other and forming a feedback loop that further undermines patient well-being (Hernández et al., 2024).

Alongside the obvious physiological impacts, social and lifestyle variables also influence outcomes. Individuals with these chronic conditions frequently encounter movement limitations, sleep disruptions, and adverse effects from medications that exacerbate psychological deterioration (Kirkbride et al., 2024). Inadequate disease treatment resulting from mental symptoms therefore exacerbates outcomes for both COPD and T2D, underscoring the essential requirement for a comprehensive and integrated healthcare strategy (Tarar et al., 2024).

The interaction among mental diseases, COPD, and T2D is also affected by socioeconomic circumstances. Restricted healthcare access, financial constraints, and diminished social support exacerbate poor illness treatment and elevate psychological discomfort (Acoba, 2024). Individuals of lower socioeconomic status are disproportionately impacted by these conditions, thus intensifying health inequities. The stigma surrounding psychiatric disorders might deter patients from pursuing appropriate medical care, resulting in delayed treatments and worse outcomes (Potts & Henderson, 2020).

Recent research underscores the significance of neurological pathways, including dysregulated hypothalamic-pituitary-adrenal (HPA) axis activity, in associating these illnesses. Chronic stress, prevalent in individuals with COPD and T2D, may result in sustained activation of the HPA axis, which elevates cortisol levels and exacerbates inflammation (P & Vellapandian, 2024). This extended stress reaction may facilitate the advancement of both mental and physical disorders, emphasising the need for stress management techniques in therapeutic approaches (Palamarchuk & Vaillancourt, 2021).

This study aims to provide a comprehensive understanding of the common pathophysiological underpinnings, clinical ramifications, and prospective treatment strategies for managing patients with mental illnesses, COPD, and T2D (Moretta et al., 2024). By promoting a multidisciplinary and patient-centred methodology, healthcare practitioners may boost treatment adherence, improve quality of life, and eventually alleviate the burden of chronic illnesses on individuals and healthcare systems (Panahi et al., 2022).

2. Methodology

This narrative review was conducted following an extensive literature search of electronic databases, including PubMed, Scopus, and Web of Science. The search strategy incorporated both controlled vocabulary (MeSH terms) and free-text keywords related to chronic obstructive pulmonary disease (COPD), type 2 diabetes mellitus (T2DM), inflammation, metabolic dysregulation, and psychiatric comorbidities.

To ensure a structured and comprehensive review, the SPIDER (Sample, Phenomenon of Interest, Design, Evaluation, Research Type) framework was used, particularly to capture qualitative research addressing the psychosocial and systemic dimensions of COPD-T2DM comorbidity. The search was restricted to peer-reviewed publications from the last 5 years (2020–2025) to ensure the

inclusion of contemporary findings. Articles were included if they were published in English-language journals, while duplicate records and studies lacking sufficient methodological detail were excluded.

Two independent researchers screened titles and abstracts to identify studies that met the inclusion criteria. Potentially relevant articles underwent full-text review to confirm eligibility. Any discrepancies in study selection were resolved through discussion with a third reviewer to maintain objectivity (Table 1).

Table 1: Inclusion and Exclusion Criteria

Criteria	**Inclusion**	**Exclusion**
Language	English-language peer-reviewed articles	Non-English articles
Publication Year	2020–2025	Studies published before 2020
Study Type	Experimental studies, clinical trials, systematic reviews, meta-analyses, and qualitative studies	Opinion pieces, editorials, and case reports
Study Focus	Research on COPD, T2D, psychiatric disorders, and inflammation	Studies not addressing shared mechanisms or comorbidities
Methodological Rigor	Studies with clear research design and statistical analysis	Studies lacking methodological details

3. Shared Pathophysiological Mechanisms

3.1. Neuroinflammation and Oxidative Stress

Chronic inflammation is a critical factor in the development and progression of mental illnesses, COPD, and T2D. Elevated concentrations of pro-inflammatory cytokines, including IL-6 and TNF-α, exacerbate neuroinflammation, which has been associated with affective disorders (Kouba et al., 2024). Furthermore, oxidative stress impairs neurovascular function, thereby aggrevating both respiratory and metabolic dysfunctions. Mitochondrial failure significantly contributes to the persistence of oxidative stress, exacerbating neurological and metabolic disorders (Iheagwam et al., 2025).

Oxidative stress arises from an imbalance between the generation of reactive oxygen species (ROS) and the body's capacity to mitigate their detrimental effects via antioxidant systems. In COPD, prolonged exposure to pollutants and cigarette smoke results in increased formation of reactive oxygen species, which damages lung tissues and exacerbates systemic inflammation (Cha et al., 2023). In T2D, hyperglycaemia increases ROS generation, resulting in endothelial damage and insulin resistance. In the brain, heightened oxidative stress leads to neuronal damage and cognitive deterioration, rendering it a crucial element in mental conditions (Caturano et al., 2023).

Moreover, neuroinflammation, marked by the activation of microglia and astrocytes, intensifies oxidative stress and results in neurotransmitter abnormalities. Pro-inflammatory cytokines can disrupt serotonin, dopamine, and glutamate pathways, increasing susceptibility to depression and anxiety (Adamu et al., 2024). The extended existence of inflammation-induced oxidative stress establishes a harmful loop that exacerbates respiratory, metabolic, and mental health disorders. This underscores the necessity for therapeutic approaches aimed at mitigating oxidative stress, including the utilisation of antioxidants, lifestyle alterations, and pharmaceutical treatments (Bezerra et al., 2023).

A wealth of studies suggest that oxidative stress and systemic inflammation play a key role in disease progression across COPD, T2D, and psychiatric conditions (Ambrosino et al., 2024; Barnes, 2022). Elevated reactive oxygen species (ROS), pro-inflammatory cytokines (IL-6, TNF-α),

and mitochondrial dysfunction have been observed in all three disorders (Choi, Kim & Park, 2024). However, several counterarguments question whether these pathophysiological mechanisms are the primary cause of disease or merely secondary consequences of underlying metabolic and neurological dysfunction.

Some researchers propose that genetic predispositions, lifestyle factors, and environmental exposures may trigger disease onset, with inflammation and oxidative stress acting as amplifiers rather than root causes (Sharifi-Rad et al., 2020).

While antioxidant and anti-inflammatory therapies have demonstrated benefits in reducing markers of inflammation, their clinical efficacy in significantly altering disease progression remains mixed (Yu, Pu & Voss, 2024). Why do some patients respond well to these interventions while others do not?

Future studies should investigate whether targeting oxidative stress alone is sufficient or if multimodal therapies addressing metabolic, immune, and neurological factors simultaneously yield better outcomes.

3.2. Hypoxia and Systemic Inflammation

Hypoxia, a defining feature of COPD, has far-reaching effects on metabolic, cardiovascular, and neurophysiological function. Reduced oxygen availability leads to systemic inflammation, worsening insulin resistance in T2D and increasing neuroinflammatory responses that contribute to mental health disorders (Weinberg et al., 2024).

One of the primary responses to hypoxia is the activation of hypoxia-inducible factors (HIFs), which regulate genes involved in angiogenic remodeling, erythropoiesis, and glucose metabolism (Qannita et al., 2024). While these adaptations are beneficial in acute hypoxia, chronic hypoxia, such as in COPD, perpetuates persistent inflammatory signaling, elevates oxidative stress, and disrupts glucose regulation (Park et al., 2022).

Beyond metabolic dysfunction, hypoxia has significant cardiovascular implications. Chronic hypoxia promotes endothelial dysfunction, increasing the risk of hypertension and atherosclerosis. Elevated levels of circulating pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) contribute to endovascular inflammation and arterial stiffness, further escalating cardiovascular risk (Katkenov et al., 2024). Additionally, hypoxia-induced polycythemia and blood hyperviscosity place added strain on the heart, increasing the likelihood of pulmonary hypertension and heart failure.

Hypoxia also impacts renal function, as the kidneys are highly sensitive to oxygen fluctuations. Prolonged hypoxia disrupts renal perfusion and filtration, contributing to chronic kidney disease (CKD) and fluid retention. This exacerbates systemic hypertension and metabolic imbalances, creating a self-perpetuating cycle that worsens COPD and T2D outcomes (Wang B. et al., 2022).

This intricate link between oxygen deprivation, inflammation, and metabolic dysfunction underscores the importance of targeted interventions, such as oxygen therapy, anti-inflammatory medications, and lifestyle modifications, to reduce the harmful effects of chronic hypoxia (Bouhamida et al., 2022).

Hypoxia, frequently observed in COPD, has been implicated in systemic inflammation, insulin resistance, and neuroinflammation. The activation of hypoxia-inducible factors (HIFs) has been proposed as a key molecular mechanism linking oxygen deprivation with disease progression. However, clinical studies reveal several complexities:

Not all COPD patients develop metabolic or psychiatric comorbidities, suggesting additional influencing factors such as genetic susceptibility, medication effects, and environmental exposures (Mariniello et al., 2024).

While oxygen supplementation is widely used to manage hypoxia, prolonged exposure in some patients has been associated with increased oxidative stress, potentially exacerbating inflammation rather than alleviating it (Liang et al., 2023).

Investigating individualised oxygen therapy strategies, mitochondrial-targeted therapies, and precision medicine approaches could lead to more effective interventions tailored to specific patient subgroups.

3.3. Gut-Lung-Brain Axis

The gut-lung-brain axis denotes a complex bidirectional communication network among the gastrointestinal, respiratory, and central neurological systems. Recent studies have shown that gut dysbiosis significantly influences the pathogenesis of mental illnesses, COPD, and T2D by affecting immunological responses, systemic inflammation, and neurotransmitter synthesis (Kandpal et al., 2022).

Dysbiosis, characterised by an imbalance of gut microbiota, can result in heightened intestinal permeability, referred to as "leaky gut syndrome," allowing endotoxins such as lipopolysaccharides (LPS) to infiltrate the circulation. This mechanism induces systemic inflammation, potentially worsening pulmonary pathologies like COPD and promoting insulin resistance in T2D (Aleman, Moncada & Aryana, 2023). Furthermore, systemic inflammation impacts the central nervous system, affecting neuroinflammation, oxidative stress, and neurochimical imbalances linked to mood disorders (Table 2).

The gut microbiota is essential for the synthesis and modulation of neurotransmitters, including serotonin, dopamine, and gamma-aminobutyric acid (GABA). Alterations in microbial composition might hinder neurotransmitter pathways, contributing to depressive and anxiety disorders (Chen, Xu & Chen, 2021). Research indicates that some bacterial strains, like Lactobacillus and Bifidobacterium, have neurotrophic properties via regulating inflammation and increasing serotonin synthesis, essential for sustaining neuropsychological stability (Del Toro-Barbosa et al., 2020).

In COPD, persistent airway inflammation is associated with changes in gut microbiota via common immunological mechanisms. The activation of inflammatory mediators in the lungs can induce systemic immune responses that disturb gut microbiota equilibrium (Kayongo et al., 2023). Likewise, metabolic disruptions in T2D might modify gut microbial diversity, intensifying inflammation and further compromising lung function. This reciprocal relationship highlights the significance of gut microbiota in sustaining respiratory and metabolic health (Deli et al., 2024).

Therapeutic approaches aimed at the gut-lung-brain axis, including probiotic supplements, prebiotics, and dietary alterations, have demonstrated potential in reducing inflammation and enhancing mental health outcomes (Figure 1). Probiotics have been linked to greater insulin sensitivity in T2D, less airway inflammation in COPD, and improved emotional balance in psychiatric conditions (Basnet et al., 2024). Moreover, dietary therapies, such as fiber-rich and anti-inflammatory diets, can enhance gut microbiota diversity and diminish systemic inflammation, providing a comprehensive strategy for addressing these interconnected disorders (Wagenaar et al., 2021).

Comprehending the gut-lung-brain axis offers a novel viewpoint on illness treatment, highlighting the significance of gut health in affecting respiratory and mental health. Future research should concentrate on identifying particular microbial strains with therapeutic potential and their involvement in customised therapy for patients with COPD, T2D, and mental illnesses (Druszczynska et al., 2024).

The gut microbiota's influence on systemic inflammation, metabolic health, and neuropsychiatric function is a rapidly growing area of research (Mostafavi Abdolmaleky & Zhou, 2024). However, despite strong correlations between gut dysbiosis and disease severity, several challenges must be acknowledged:

Many studies demonstrate an association between altered microbiota composition and chronic diseases, but it remains unclear whether these changes precede disease onset or occur as a result of disease progression (Hrncir, 2022; Mu, Rusip & Florenly, 2024).

The composition of the gut microbiome is highly individualised, influenced by genetics, diet, lifestyle, and medication use. This variability makes it difficult to establish universal microbiome-based treatments applicable to all patients (Schupack et al., 2022).

While some probiotic and prebiotic therapies have shown promise in reducing inflammation and improving metabolic function, results are inconsistent across studies (Oudat & Okour, 2025; Rau et al., 2024). More well-controlled, large-scale clinical trials are needed to determine which bacterial strains and dietary interventions have clinically significant and reproducible benefits.



Figure 1. Gut-Lung-Brain Axis

3.4. Autonomic Nervous System Dysregulation

The autonomic nervous system (ANS) is essential for maintaining homeostasis through the regulation of circulatory, respiratory, metabolic, and immunological processes. The dysregulation of the autonomic nervous system is widely acknowledged as a pivotal element in the pathogenesis of mental illnesses, COPD, and T2D (Hamrefors, 2023). This dysregulation presents as an imbalance between the sympathetic and parasympathetic nervous systems, leading to persistent inflammation, metabolic abnormalities, and affective disturbances (Bellocchi et al., 2022).

Patients with COPD and T2D exhibit a hyperactive sympathetic nervous system (SNS), resulting in elevated levels of stress hormones, including cortisol and catecholamines. This persistent stress response intensifies systemic inflammation, oxidative stress, and insulin resistance, establishing a detrimental loop that exacerbates disease development (Dawi et al., 2024). In mental diseases, increased sympathetic nervous system activity correlates with anxiety, depression, and cognitive impairment, hence complicating disease management.

In contrast, diminished parasympathetic nervous system (PNS) function, especially decreased vagal tone, has been associated with worse outcomes in COPD, T2D, and mental disorders. The vagus nerve is essential in regulating inflammatory responses via the cholinergic anti-inflammatory pathway (Fornaro et al., 2022). Decreased vagal activity has been associated with heightened systemic inflammation, compromised glucose metabolism, and an increased vulnerability to mood disorders. Recent research indicates that therapies designed to restore vagal tone, including vagus nerve stimulation (VNS), mindfulness techniques, and aerobic exercise, may have therapeutic advantages in the management of various diseases (Bazoukis, Stavrakis & Armoundas, 2023).

Heart rate variability (HRV), an essential measure of ANS, is often diminished in persons with COPD, T2D, and mental illnesses. Reduced HRV indicates autonomic rigidity and correlates with heightened mortality risk and illness severity (Agorastos et al., 2023). Methods to enhance

heart rate variability, including respiratory exercises, biofeedback, and physical exercise, may aid in reestablishing autonomic equilibrium and alleviating illness load.

Moreover, the gut microbiota has demonstrated interactions with the autonomic nervous system, affecting systemic inflammation and neurotransmitter modulation. Disruptions in gut microbiota composition can lead to ANS dysfunction, further perpetuating metabolic, respiratory, and mental problems (Ojeda, Ávila & Vidal, 2021). Subsequent study should investigate gut-brain-autonomic nervous system connections as prospective therapeutic targets for holistic therapeutic strategies (Lu et al., 2024).

Understanding the significance of ANS dysregulation in COPD, T2D, and mental illnesses highlights the necessity for multidisciplinary therapeutic approaches. Interventions designed to mitigate SNS overactivation and augment PNS function may increase therapeutic results, improve quality of life, and alleviate the burden of these interrelated disorders (Goldstein, 2021) (Figure 2).

Table 2. Summary of Key Pathophysiological Mechanisms

Pathophysiological Mechanism	COPD Impact	T2D Impact	Psychiatric Impact
Oxidative Stress	Damages lung tissue, increases inflammation	Promotes insulin resistance, endothelial dysfunction	Impairs neurotransmitter balance, contributes to cognitive decline
Neuroinflammation	Exacerbates airway inflammation	Alters insulin signaling, increases risk of neurodegeneration	Associated with depression, anxiety, and mood disorders
Hypoxia and HIF Activation	Reduces oxygen delivery, triggers systemic inflammation	Aggravates insulin resistance, affects vascular health	Contributes to anxiety, cognitive impairment, and sleep disturbances
Gut Dysbiosis	Alters immune response, increases systemic inflammation	Affects glucose metabolism, promotes metabolic dysfunction	Influences serotonin production, impacts mental health
Autonomic Nervous System Dysregulation	Increases sympathetic activity, reduces parasympathetic tone	Disrupts glucose homeostasis, promotes hypertension	Correlates with anxiety, depression, and cardiovascular risk



Figure 2. Comparison of the prevalence of key biological mechanisms in individuals with COPD and T2D versus the general population. The chart highlights the increased impact of inflammation, oxidative stress, hypoxia, gut dysbiosis, and systemic dysfunction in the comorbid population

4. Clinical Implications and Comorbidities

The clinical implications of the interaction among mental illnesses, COPD, and T2D are significant, influencing disease progression, treatment compliance, and health-related quality of life (HRWoL). Individuals with these comorbid diseases frequently endure more acute symptoms and inferior clinical outcomes relative to individuals with a singular disorder (Anghel et al., 2025). The bidirectional nature of these illnesses produces a loop of deteriorating symptoms, where mental issues can accelerate COPD and T2D development, while metabolic and respiratory dysfunctions contribute to psychological distress (Rahi et al., 2023).

4.1. Psychiatric Disorders in COPD and Diabetes

Incidence of depression and anxiety in patients with COPD and T2D. Research demonstrates a significant occurrence of psychological illnesses, especially depression and anxiety, among patients with COPD and T2D. The ongoing stress of chronic disease management, together with systemic inflammation and neurochemical changes, heightens susceptibility to mental health disorders (Rahi et al., 2023). Depression influences around 40% of COPD patients and 25% of those with T2D, considerably impairing their capacity to comply with treatment protocols and participate in self-care activities (Neale et al., 2022).

Common neurobiological mechanisms. Shared pathophysiological mechanisms, including neuroinflammation, oxidative stress, and dysregulated hypothalamic-pituitary-adrenal (HPA) axis function, connect COPD, T2D, and psychiatric disorders. Chronic systemic inflammation disturbs neurotransmitter equilibrium, resulting in emotional instability and cognitive deficits, hence increasing the illness load (Mikulska et al., 2021). Additionally, alterations in the gut microbiota have been connected with higher anxiety and depression symptoms, underlining the need for a comprehensive approach to therapy (Xiong et al., 2023).

Effect on cognitive function. COPD and T2D are associated with cognitive deficits resulting from persistent hypoxia, oxidative stress, and vascular dysfunction. Decreased oxygen delivery to the brain, together with metabolic irregularities, leads to memory impairments, diminished executive function, and reduced cognitive processing speed, heightening the risk of dementia and exacerbating mental symptoms (Siraj, 2023).

Sleep disturbances and psychiatric burden. Many patients with COPD and T2D have sleep difficulties, such as insomnia, sleep apnea, and restless leg syndrome. Poor sleep quality aggravates mood disorders, elevates systemic inflammation, and disrupts glucose metabolism, establishing a feedback loop that deteriorates both mental and physical health consequences (Clímaco et al., 2022).

4.2. Increased Disease Burden and Complications

Worsening disease prognosis. Individuals with psychiatric comorbidities have a more significant deterioration in pulmonary and metabolic function, resulting in elevated hospitalisation rates and increased mortality risks. Research demonstrates that depression and anxiety correlate with worse illness outcomes, since they might exacerbate inflammatory processes and diminish adherence to medical treatments (Rahi et al., 2023). COPD patients with concomitant depression had greater exacerbation rates and lower lung function, whereas T2D patients with psychiatric illnesses exhibit worse glycemic control and an increased risk of cardiovascular consequences (Moretta et al., 2024).

Impact of stress and inflammation. Psychological stress and mood disorders increase pro-inflammatory cytokine leveles, worsening the course of COPD and T2D while compromising immunological function (Park et al., 2022). Chronic stress may cause dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, resulting in elevated cortisol levels that contribute to insulin resistance and systemic inflammation (P & Vellapandian, 2024). Moreover, stress-induced behaviours, like smoking, poor dietary choices, and lack of physical activity, exacerbate pulmonary and metabolic problems (Rahelić et al., 2024).

Association with multimorbidity. Patients with psychiatric conditions, COPD, and T2D typically develop other chronic diseases, including hypertension, cardiovascular disease, and obesity (Hughes, McGettrick & Sapey, 2020). This multimorbidity complicates therapy and necessitates a thorough, multidisciplinary care strategy. Studies demonstrate that treating psychological symptoms can lead to improved management of COPD and T2D, stressing the necessity of early intervention and integrated care paradigms (Schrijver et al., 2022).

Effects on physical activity and disability. Depression and anxiety correlate with decreased physical activity levels, which exacerbate symptoms of COPD and T2D. Impaired mobility and exercise intolerance exacerbate muscular atrophy, insulin resistance, and respiratory deterioration (Selzler et al., 2023). This leads to greater disability rates and dependency on healthcare services, further compromising the patient's quality of life and overall prognosis.

Sleep disturbances and complications. Sleep problems, such as obstructive sleep apnea (OSA), are highly prevalent in people with COPD and T2D and are typically associated with psychological illnesses (Fanaridis & Bouloukaki, 2024). Poor sleep quality leads to increasing respiratory symptoms, increased insulin resistance, and heightened depressed and anxiety symptoms, continuing a cycle of poor health consequences (Anghel et al., 2023; Scott et al., 2021).

4.3. Impact on Treatment Adherence and Self-Management

Challenges in medication adherence. Individuals with COPD and T2D who also suffer from psychological problems encounter substantial difficulties in adhering to prescribed medication regimes. Depression and anxiety can lead to forgetfulness, lack of desire, and heightened emotions of helplessness, all of which contribute to poor compliance (Marculescu et al., 2019; Volpato et al., 2021). Patients may miss dosages, forget to renew prescriptions, or take drugs inconsistently, leading to exacerbations of both physical and mental health disorders.

Effects of psychological distress on lifestyle management. Effective self-management of COPD and T2D needs commitment to lifestyle adjustments such as frequent physical exercise, smoking cessation, and nutritional restriction (Schrijver et al., 2022). However, mental problems can impede these attempts by lowering motivation and increasing involvement in maladaptive behaviours. Anxiety and depression may lead to emotional eating, less physical activity, and persistent tobacco use, all of which exacerbate illness consequences (Taylor, 2021).

Cognitive impairments and self-care difficulties. Cognitive impairment, typically linked with mental diseases, might further impair treatment adherence. Executive function deficiencies, such as poor decision-making and diminished problem-solving skills, can impair a patient's ability to follow medical advice, monitor symptoms, or identify when professional help is essential (Esmaili et al., 2023). This poses significant challenges for patients with intricate treatment protocols necessitating frequent blood glucose testing, inhaler utilisation, and drug modifications.

Fear and avoidance behaviours. Patients with anxiety disorders may develop a phobia of medical interventions, leading to avoidance of healthcare appointments and noncompliance with treatments such as insulin therapy or pulmonary rehabilitation (Baryakova et al., 2023). Certain persons may hesitate to participate in physical activity because of apprehensions over dyspnea or variations in blood sugar, hence aggravating disease development (Kanaley et al., 2022).

Social and economic barriers. Psychiatric disorders can contribute to social isolation and financial issues, both of which significantly impair self-management. Individuals with depression or anxiety may lack the social support needed to sustain treatment adherence, while economic difficulties may prohibit them from obtaining critical drugs, healthy dietary alternatives, and healthcare services (Brandt et al., 2022).

Role of integrated care strategies. Addressing psychiatric disorders in COPD and T2D patients is critical for increasing adherence and self-management. Integrated treatment techniques that assimilate mental health therapies with medical management, such as cognitive-behavioural therapy (CBT) alongside pulmonary or diabetic care, have shown promise in boosting adherence and overall health results (Moretta et al., 2024). Regular psychological support, patient education

programs, and streamlined pharmaceutical protocols may help alleviate the hurdles to effective illness treatment.

4.4. Bidirectional Influence on Mental Health and Physical Disease

Psychiatric disorders exacerbating physical health conditions. Chronic psychological illnesses, including depressive symptomatology and anxiety, coexist with COPD and T2D and exacerbate their development (Rahi et al., 2023). Psychological stress elevates cortisol and other stress-related chemicals, resulting in inflammation, insulin resistance, and diminished lung function. Anxiety-induced hyperventilation may aggravate respiratory symptoms, whereas inactivity associated with major depressive disorder (MDD) might deteriorate glycemic control in diabetes (Yaribeygi et al., 2022).

Impact of chronic illness on mental health. The coexistence of COPD and T2D markedly elevates the probability of developing psychiatric conditions owing to the stress associated with chronic illness treatment, physical constraints, and diminished quality of life (Moretta et al., 2024). Patients experiencing dyspnea in COPD may encounter panic attacks or generalised anxiety disorder, whereas those with T2D may suffer from depressive symptoms as a result of the demands of continuous glucose monitoring and dietary limitations (Rahi et al., 2023).

Neuroinflammation as a shared mechanism. Recent studies suggest that systemic inflammation linked to COPD and T2D affects the brain, resulting in neuroinflammation and alterations in neurotransmitter activity (Park et al., 2022) Elevated concentrations of pro-inflammatory cytokines, including IL-6 and TNF-α, have been associated with both depression and cognitive deterioration, underscoring the relationship between these disorders (Elgellaie et al., 2023).

Cognitive decline and disease management challenges. COPD and T2D are linked to cognitive impairments, such as memory deficiencies and executive dysfunction, which can hinder a patient's capacity to manage their illness successfully (Siraj, 2023). Impaired cognitive function hinders patients from adhering to drug regimens, following dietary guidelines, or participating in pulmonary rehabilitation, resulting in disease advancement and heightened hospitalisations (Almdabgy et al., 2023).

4.5. Practical Implications for Clinical Decision-Making and Healthcare Systems

The mind-lung-metabolism axis presents a compelling framework for understanding the interplay between psychiatric disorders, COPD, and T2D. However, translating these findings into effective clinical and healthcare system strategies remains a critical challenge. The high prevalence of neuropsychiatric and cartiometabolic comorbidities in respiratory patients necessitates a paradigm shift from isolated disease management to a comprehensive, multidisciplinary approach. Several key recommendations emerge from this review that can directly influence clinical decision-making and healthcare policies.

Early Screening and Risk Stratification: Early identification of at-risk patients is essential to preventing disease progression and improving patient outcomes. Current clinical workflows often treat COPD, T2D, and psychiatric disorders separately, leading to fragmented care (Choi & Rhee, 2020). A more integrated approach would involve:

- Routine mental health screening for patients diagnosed with COPD and T2D, using standardised tools such as the Patient Health Questionnaire (PHQ-9) for depression and the Generalised Anxiety Disorder (GAD-7) scale for anxiety (Liu et al., 2023).
- Incorporation of predictive biomarker panels (e.g., inflammatory cytokines like IL-6, TNF-α, and CRP) into routine diagnostics to detect early signs of neuroinflammation and metabolic dysregulation (Rauf et al., 2022).
- Risk stratification algorithms that use electronic health records (EHRs) and machine learning to identify high-risk patients who may benefit from more intensive multidisciplinary interventions (Lee et al., 2020).

- Enhanced screening protocols for sleep disturbances, given the strong association between obstructive sleep apnea, insulin resistance, and mood disorders in COPD and T2D patients (Karuga et al., 2023).

Multidisciplinary and Integrated Care Models: Given the complex interplay of these conditions, interdisciplinary collaboration is crucial. Traditional siloed treatment approaches fail to address the reciprocal nature of these diseases, which exacerbate each other when treated in isolation (Lau et al., 2024). Strategies for improvement include:

- Establishment of specialised "Metabolic-Respiratory-Psychiatric" (MRP) clinics, where pulmonologists, endocrinologists, and psychiatrists co-manage patients with overlapping conditions (Recio Iglesias et al., 2020).
- Promotion of integrated care teams in primary care and hospital settings, ensuring that mental health assessments are routinely included in COPD and T2D management (Poot, 2021).
- Implementation of shared decision-making (SDM) models, where patients actively participate in treatment planning, improving adherence to medications and lifestyle modifications (Montori et al., 2023).
- Expansion of telemedicine and digital health solutions, including remote patient monitoring and AI-driven diagnostic tools, to facilitate continuous care and early intervention (Ezeamii et al., 2024).

Treatment Personalisation and Emerging Therapies: Advances in precision medicine and neuroinflammation-targeting treatments hold promise for patients suffering from overlapping metabolic, respiratory, and psychiatric disorders. Clinicians should consider:

- Anti-inflammatory therapies targeting shared pathways in COPD, T2D, and depression, such as IL-6 inhibitors, TNF-α blockers, and antioxidants (Cazzola et al., 2023).
- Gut microbiota-based interventions, including probiotics and dietary modifications, to modulate neuroinflammation and metabolic dysfunction (Perrone & D'Angelo, 2025).
- Psychotropic medications with dual benefits, such as SSRIs that have anti-inflammatory properties, potentially mitigating both mood disorders and systemic inflammation (Mechlińska et al., 2023).
- Behavioural interventions such as Cognitive-Behavioural Therapy (CBT), mindfulness-based stress reduction (MBSR), and structured physical activity programs, which have demonstrated positive effects on inflammation, insulin sensitivity, and lung function (Vargas-Uricoechea et al., 2024).
- Neuromodulation therapies like vagus nerve stimulation (VNS) and transcranial magnetic stimulation (TMS) as potential treatments for treatment-resistant depression and dysautonomia (Idlett-Ali et al., 2023).

Healthcare System-Level Policy Recommendations: Beyond clinical interventions, system-wide policy changes are necessary to support long-term integration of care. Policymakers should focus on:

- Embedding mental health services within primary care and specialty clinics treating COPD and T2D to ensure early psychiatric intervention and preventive care (Schrijver et al., 2022).
- Insurance and reimbursement reforms that cover multidisciplinary treatments, including mental health therapy, lifestyle interventions, and integrated disease management programs.
- Investing in public health campaigns to raise awareness of the interconnected nature of respiratory, metabolic, and psychiatric disorders, reducing stigma and encouraging preventive healthcare-seeking behaviours (Semrau et al., 2023).
- Developing national guidelines for integrated chronic disease management, emphasising the role of shared pathophysiological mechanisms in shaping treatment approaches (Coman et al., 2024).

- Expanding research funding for precision medicine approaches, AI-driven diagnostics, and microbiome-targeted therapies to identify optimised and startified treatment pathways (Ho et al., 2020).

5. Therapeutic Approaches

The intricate relationship among mental illnesses, COPD, and T2D requires a comprehensive therapeutic strategy. Due to the same pathophysiological pathways, tailored treatments that focus on inflammation, oxidative stress, autonomic dysregulation, and metabolic dysfunction are crucial for optimal illness management (Miravitlles, 2023). Comprehensive therapy approaches, encompassing pharmaceutical, psychological, and lifestyle treatments, offer great opportunities for enhancing patient outcomes.

5.1. Importance of Early Screening for Comorbidities

Early detection and intervention. Early identification of mental illnesses, COPD, and T2D might enhance patient outcomes through prompt therapy. Screening initiatives in general care and specialist clinics can facilitate the identification of patients at risk for certain illnesses prior to substantial disease advancement (Lin et al., 2023). Early screening in high-risk populations, including older persons and those with a familial predisposition to metabolic or respiratory diseases, is essential for mitigating consequences.

Integration of screening tools. Employing standardised screening instruments for depression, anxiety, metabolic disorders, and pulmonary function can enhance early diagnosis and treatment strategy formulation. Integrating physical health assessments with mental health evaluations can result in more holistic patient treatment (Clemente-Suárez et al., 2023). Interdisciplinary collaboration among general practitioners, pulmonologists, endocrinologists, and mental health experts may guarantee that screening initiatives address the comprehensive range of patient health requirements (Braam et al., 2022).

Benefits of proactive management. Early therapies, including lifestyle adjustments, psychological counseling, and pharmaceutical treatments, can avert symptom worsening and enhance illness prognosis. Early intervention in comorbidities can improve long-term quality of life and decrease healthcare expenditures. Evidence indicates that early intervention can enhance medication adherence and decrease hospitalisation rates by fostering patient involvement in illness self-management (Religioni et al., 2025).

Barriers to early screening and potential solutions. Despite the benefits of early screening, some obstacles persist, such as restricted healthcare access, patient hesitance to participate in screenings owing to stigma, and the absence of standardised screening techniques (Reynolds et al., 2022). Overcoming these obstacles necessitates public health programs that enhance awareness of the significance of early detection, educate healthcare practitioners in doing thorough screenings, and utilise digital health technologies for remote monitoring and evaluation (Mumtaz et al., 2023).

5.2. Pharmacological Interventions

Anti-inflammatory therapies. Considering the impact of systemic inflammation on the advancement of COPD, T2D, and mental disorders, anti-inflammatory pharmacotherapies, including corticosteroids, NSAIDs, and biologic medicines aimed at cytokines such as IL-6 and TNF-α, may alleviate disease burden. These therapies assist in regulating inflammation, averting tissue damage, and enhancing overall illness prognosis (Lea et al., 2023).

Neuroprotective and psychotropic agents. Medications like selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) not only mitigate depression and anxiety but also provide anti-inflammatory and neuroprotective effects (Bonilla-Jaime et al., 2022; Abu Shehab et al., 2021). Their dual mechanism renders them effective

in addressing mental symptoms while perhaps alleviating cognitive deterioration linked to COPD and T2D.

Metabolic and cardiovascular agents. Medications such as metformin enhance insulin sensitivity and provide anti-inflammatory properties, establishing them as fundamental in the treatment of T2D, with possible advantages in psychiatric conditions (Herman et al., 2022). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have neuroprotective and anti-inflammatory effects, hence reinforcing their application in multimorbid disorders (Alharbi, 2024).

Bronchodilators and respiratory support. Long-acting bronchodilators and inhaled corticosteroids are crucial for the management of COPD and the prevention of exacerbations that may lead to systemic inflammation (Duan, Li & Yang, 2023). These medicines enhance pulmonary function, mitigating hypoxia-related consequences that might aggravate mental and metabolic problems.

Combination therapies. Employing multi-target strategies, such as the integration of anti-diabetic treatments with antidepressants or anti-inflammatory medications, may enhance results by targeting the interrelated pathways associated with COPD, T2D, and mental disorders (Cazzola et al., 2023). Investigations into precision medicine methodologies seek to customise pharmacological treatments according to specific patient characteristics.

5.3. Psychological and Behavioural Interventions

Cognitive-behavioural therapy (CBT). Cognitive Behavioural Therapy (CBT) is a validated, evidence-based approach that assists patients in cultivating coping strategies to address stress, anxiety, and depression. This therapy is essential for improving self-management of COPD and T2D by promoting motivation, medication adherence, and general psychological well-being (Williams, Johnston & Paquet, 2020). Consistent CBT sessions, conducted either face-to-face or via telemedicine, have demonstrated considerable efficacy in alleviating symptom severity in mental illnesses and managing chronic diseases (Luo et al., 2020).

Mindfulness-based stress reduction (MBSR). MBSR procedures, including guided meditation and regulated breathing exercises, have been shown to decrease systemic inflammation, lower stress hormone levels, and enhance emotional regulation. Integrating MBSR into disease care can assist patients with COPD and T2D in managing chronic illness-related anxiety, hence improving their quality of life and overall resilience (Zhang et al., 2021).

Behavioural activation therapy. This method emphasises involving individuals in significant and fulfilling activities to mitigate depressed symptoms. Behavioural activation has been shown to be particularly beneficial in disrupting cycles of inactivity prevalent in patients with COPD and T2D, fostering physical exercise, improved nutritional practices, and constructive social contacts (Rethorst et al., 2023).

Pulmonary and metabolic rehabilitation with psychological support. Comprehensive rehabilitation programs that incorporate physical therapy, dietary counseling, and psychological assistance have demonstrated favourable outcomes in enhancing pulmonary function, glycemic regulation, and mental well-being (Nambi et al., 2023). These initiatives underscore the need for a systematic and thorough methodology for illness management, alleviating disease burden and enhancing compliance with prolonged treatment regimens.

Social support interventions. Group therapy and peer support programs provide psychological advantages by alleviating feelings of isolation, prevalent among patients with chronic illnesses. Participation in community-oriented mental health programs or online support groups might assist individuals with COPD and T2D in fostering a feeling of belonging, enhancing emotional resilience, and promoting good lifestyle choices (Joo et al., 2022).

Motivational interviewing (MI). Motivational Interviewing (MI) is a patient-centred therapy methodology aimed at enhancing intrinsic motivation and addressing ambivalence around behavioural modification. It has demonstrated efficacy in enhancing compliance with treatment

protocols, facilitating smoking cessation, managing weight, and increasing physical activity in persons with COPD and T2D (Bischof, Bischof & Rumpf, 2021).

5.4. Lifestyle Modifications

Dietary adjustments and nutrition therapy. A proper diet is essential for the management of COPD, T2D, and mental illnesses. An optimal diet abundant in anti-inflammatory foods, whole grains, lean proteins, and healthy fats can assist in regulating blood glucose levels, diminishing systemic inflammation, and enhancing pulmonary function (Kurowska et al., 2023). Nutritional counseling and meal planning can aid patients in implementing lasting dietary modifications that enhance overall health and well-being.

Regular physical activity and exercise. Regular physical exercise has been demonstrated to augment lung capacity, increase insulin sensitivity, and mitigate symptoms of despair and anxiety. Aerobic activities, like walking, swimming, and cycling, in conjunction with weight training, can substantially enhance patients' cardiovascular health and total metabolic performance. Customised exercise regimens, including pulmonary rehabilitation and organised fitness protocols, should be actively promoted (Syeda et al., 2023).

Smoking cessation and avoidance of pollutants. Smoking significantly exacerbates the course of COPD and intensifies systemic inflammation, hence aggravating metabolic and mental disorders. Smoking cessation programs, nicotine replacement medicines, and behavioural therapy can assist patients in quitting smoking and mitigating their risk of illness aggravation. Moreover, evading air pollution and other environmental contaminants can safeguard pulmonary health and general well-being (Iida et al., 2021).

Sleep hygiene and stress management. Poor sleep quality is associated with heightened inflammation, insulin resistance, and psychological disorders. Adopting sleep hygiene techniques, including adhering to a consistent sleep schedule, minimising screen exposure before bedtime, and establishing a conducive sleep environment, can markedly enhance sleep quality. Stress management strategies, such as mindfulness, meditation, and deep breathing exercises, can augment relaxation and improve overall illness management (Alanazi et al., 2023).

Alcohol and substance use moderation. Excessive use of alcohol and substances can adversely affect metabolic function, pulmonary health, and mental health stability. Promoting the reduction of alcohol consumption and encouraging patients to get assistance for drug dependency via counseling and rehabilitation programs can markedly enhance overall disease outcomes (MacKillop et al., 2022).

Patient education and self-care empowerment. Educating patients about their diseases and enabling them to have an active part in disease management is essential. Facilitating access to instructional materials, self-care instruments, and community support networks can augment treatment compliance and boost long-term health outcomes. Motivating patients to monitor symptoms, medicines, and lifestyle changes can enhance accountability and support ongoing well-being (Vainauskienė & Vaitkienė, 2021).

5.5. Psychoducation for Patients and Their Families on Managing the Emotional Impact.

Chronic conditions like COPD and T2D impact patients physiologically and also have significant emotional and psychological consequences on both patients and their families. Educating individuals on identifying emotional discomfort, employing coping strategies, and pursuing professional assistance is crucial for managing the psychosocial impact of these diseases. Family members are essential in assisting patients with lifestyle modifications, treatment compliance, and mental health issues (Menear et al., 2022).

Understanding emotional distress in chronic illness. Individuals with COPD and T2D often encounter worry, melancholy, frustration, and dread over disease advancement and therapeutic protocols. Family members may experience emotions of powerlessness and emotional exhaustion.

Providing tools that elucidate the emotional issues linked to chronic disease can assist both patients and caregivers in managing these difficulties (Rahi et al., 2023).

Developing coping mechanisms. Instructing patients and their families in good coping skills, including stress reduction approaches, mindfulness practices, and relaxation methods, can markedly enhance mental well-being. Promoting transparent dialogue on emotions and difficulties helps foster a nurturing home atmosphere advantageous to both patients and caregivers (Zandi et al., 2021).

Accessing professional mental health support. Referring individuals to mental health specialists, including psychologists and social workers, can be crucial in alleviating the emotional and psychological strain of chronic conditions. Counseling services, family therapy, and support groups help strengthen emotional resilience and avert caregiver burnout (Posluns & Gall, 2020).

Workshops and educational sessions. Implementing organised educational programs centred on mental health management, coping strategies, and caregiver assistance may empower patients and their families. These seminars offer pragmatic strategies for managing emotional stress and addressing the intricacies of chronic disease management (Lohrasbi et al., 2023).

Encouraging family involvement in disease management. Families are essential in facilitating treatment adherence and fostering healthy behaviours. Instructing family members on medication administration, food planning, and exercise regimens can promote a cooperative strategy for controlling COPD and T2D, resulting in enhanced patient outcomes and quality of life (Cross et al., 2020).

Reducing stigma and fostering emotional resilience. Numerous patients and caregivers experience isolation stemming from the stigma associated with chronic diseases and mental health disorders. Fostering a culture of transparency and education may diminish stigma, promote proactive mental health treatment, and enhance overall well-being for patients and their families (Søvold et al., 2021).

6. Future Research Directions

Future research should focus on developing a deeper understanding of the mind-lung-metabolism axis and its implications for integrated disease management. Several key areas warrant further investigation.

Personalised medicine and biomarker discovery. Progress in genomes, proteomics, and metabolomics may facilitate the development of biomarkers that forecast disease progression and therapeutic response. Comprehending individual genetic and epigenetic variants might enable individualised therapy approaches customised for individuals with COPD, T2D, and mental diseases.

The role of the gut microbiome in systemic inflammation and neuroinflammation. Recent data indicate that changes in gut microbiota have a role in the onset and advancement of COPD, T2D, and mental disorders. Future research should investigate the effects of microbiome-targeted therapies, including probiotics, prebiotics, and dietary alterations, on illness outcomes.

Longitudinal studies on the bidirectional nature of these conditions. Although the associations among mental illnesses, COPD, and T2D are well-established, longitudinal investigations are required to ascertain causation and find early prognostic markers. Observational and interventional cohort studies can elucidate illness trajectories and assess the efficacy of early therapies.

Integration of digital health technologies. The exploration of wearable gadgets, mobile health applications, and telemedicine for illness monitoring and management warrants more investigation. Digital technologies can enhance medication adherence, monitor disease development, and enable real-time treatments for patients with multiple comorbidities.

Evaluating the efficacy of multidisciplinary care models. Research ought to concentrate on evaluating integrated healthcare methodologies that amalgamate pulmonology, endocrinology,

psychiatry, and primary care. Examining the cost-effectiveness and clinical advantages of coordinated care models might inform future healthcare policy and enhance patient outcomes.

Innovative pharmacological and non-pharmacological treatments. Future research should investigate innovative pharmacological strategies that tackle the same inflammatory, metabolic, and neurodegenerative processes associated with COPD, T2D, and mental diseases. Furthermore, exploring non-pharmacological therapies, including neuromodulation techniques (e.g., transcranial magnetic stimulation, vagus nerve stimulation), may provide novel strategies for symptom management.

By advancing research in these areas, the medical community can work towards more effective, patient-centred treatment strategies that improve quality of life and reduce the burden of these interrelated chronic conditions.

7. Discussions

The findings of this review highlight the interconnected nature of psychiatric disorders, COPD, and T2D, emphasising shared mechanisms such as neuroinflammation, oxidative stress, systemic inflammation, hypoxia, and gut dysbiosis. These overlapping pathways contribute to disease progression and underscore the necessity for an integrated healthcare approach. Addressing these mechanisms collectively, rather than treating each disease in isolation, may enhance patient outcomes and reduce long-term morbidity (Øvretveit, Hansson & Brommels, 2010).

A key takeaway from this review is the importance of multidisciplinary collaboration in managing patients with these comorbid conditions. Given the intricate links between respiratory, metabolic, and psychiatric health, healthcare providers must adopt a holistic treatment framework that incorporates early screening protocols, integrated care models, and personalised treatment plans (Stein et al., 2022). Routine assessment of mental health symptoms in COPD and T2D patients can facilitate early intervention, reducing the burden of untreated psychiatric disorders. Coordination between pulmonologists, endocrinologists, and psychiatrists is critical in providing comprehensive management plans, and leveraging advances in precision medicine and biomarker-driven therapies can optimise treatment efficacy for individual patients (Moretta & Cavallo, 2024).

Recent advances in precision medicine and AI-driven diagnostics have the potential to revolutionise the management of these interconnected conditions. Precision medicine, through advancements in genomics, transcriptomics, and biomarker-driven therapies, allows for personalised treatment approaches targeting inflammation, oxidative stress, and metabolic dysfunction (Marques & Costa, 2024). Future therapies may include anti-inflammatory biologics tailored to specific patient profiles and targeted mitochondrial therapies to mitigate oxidative stress. AI-driven diagnostics, including machine learning models that analyse vast datasets from electronic health records, imaging, and biomarker panels, offer predictive capabilities for disease progression, optimising treatment plans, and enhancing early screening for at-risk populations (R. C. Wang & Wang, 2023). AI-based tools are increasingly being used to detect COPD exacerbations, metabolic dysregulation in T2D, and psychiatric symptom onset in preclinical stages. Microbiome-based interventions, such as probiotics, prebiotics, and dietary modifications, have gained attention as a potential strategy to mitigate systemic inflammation and improve metabolic and mental health outcomes (Robertson, Centner & Siddharthan, 2024). Additionally, the development of targeted anti-inflammatory therapies, including IL-6 and TNF-α inhibitors, and neuromodulatory interventions, such as vagus nerve stimulation, presents promising avenues for managing chronic inflammation and autonomic dysregulation (Liu & Wu, 2024).

While this review provides valuable insights into the interplay between respiratory, metabolic, and psychiatric disorders, several limitations should be acknowledged. The included literature varies widely in terms of study design, population demographics, and methodological rigor, limiting direct comparisons across findings (Elendu et al., 2024). Most studies reviewed are cross-sectional, making it difficult to determine causal relationships between systemic inflammation, hypoxia, oxidative stress, and disease progression. Although precision medicine,

AI-based diagnostics, and microbiome interventions show promise, more large-scale clinical trials are needed to validate their long-term efficacy in managing COPD, T2D, and psychiatric comorbidities (Johnson & Wei, 2021). The impact of diet, exercise, air pollution, and socioeconomic determinants on disease progression remains underexplored and should be considered in future research.

8. Conclusion

The complex interplay of mental diseases, COPD, and T2D highlights the necessity for a thorough, multidisciplinary strategy in patient management. These disorders are interrelated, interacting through common pathophysiological pathways that exacerbate one another and complicate illness treatment. Comprehending these linkages allows healthcare practitioners to execute comprehensive, patient-focused therapy approaches that cater to both bodily and emotional health requirements.

Early detection and treatment are essential in alleviating the detrimental impacts of these comorbid disorders. Conducting regular screenings, including mental health support into chronic illness care, and advocating for patient education can markedly improve treatment compliance and overall health. The significance of social determinants of health must not be overlooked, since economic, environmental, and psychological variables profoundly affect illness outcomes. Targeted initiatives addressing these larger variables can mitigate healthcare inequities and enhance access to comprehensive care.

Future research should persist in investigating novel treatment strategies, including precision medicine, microbiome-centric remedies, and neuromodulation methodologies. The incorporation of digital health technology, including telemedicine and wearable devices, presents significant prospects for real-time illness surveillance and individualised treatment strategies. Additionally, greater exploration of the gut-lung-brain axis and systemic inflammation may provide new targets for therapeutic intervention.

Ultimately, effective management of COPD, T2D, and psychiatric disorders necessitates a transition to proactive, multidisciplinary care. By promoting collaboration among pulmonologists, endocrinologists, mental health experts, and primary care doctors, healthcare systems can optimise patient outcomes and improve quality of life. An integrated, patient-centred treatment strategy that incorporates both biological and psychological components will be essential in tackling the increasing burden of these interconnected chronic illnesses.

Furthermore, increased focus should be directed to long-term illness prevention efforts, encompassing public health initiatives, community-based support programs, and awareness campaigns. Equipping patients with essential resources, skills, and information to manage their illnesses proficiently can enable them to assume an active part in their health and well-being. Augmenting caregiver support, advocating self-management techniques, and cultivating mental health resilience can further enhance patient outcomes and quality of life.

With the global increase in these comorbid illnesses, healthcare systems must evolve by including comprehensive care models that emphasise both prevention and treatment. The future of chronic illness treatment depends on integrating physical and mental health care, assuring comprehensive attention to a patient's well-being through new, evidence-based approaches.

References

Abu Shehab, A. H. I., Anghel, L., Stefanescu, B. I., Kantor, C., & Ciubara, A. (2021). Prevention of psychoactive substance use. *Archiv Euromedica, 11*(5), 59–61. https://doi.org/10.35630/2199-885X/2021/11/5.16

Acoba, E. F. (2024). Social support and mental health: The mediating role of perceived stress. *Frontiers in Psychology, 15*, 1330720. https://doi.org/10.3389/fpsyg.2024.1330720

Adamu, A., Li, S., Li, S., Gao, F., Gao, F., Xue, G. (2024). The role of neuroinflammation in neurodegenerative diseases: Current understanding and future therapeutic targets. *Frontiers in Aging Neuroscience, 16*, 1347987. https://doi.org/10.3389/fnagi.2024.1347987

Agorastos, A., Mansueto, A. C., Hager, T., Pappi, E., Gardikioti, A., & Stiedl, O. (2023). Heart rate variability as a translational dynamic biomarker of altered autonomic function in health and psychiatric disease. *Biomedicines, 11*(6), 1591. https://doi.org/10.3390/biomedicines11061591

Alanazi, E. M., Alanazi, A. M. M., Albuhairy, A. H., & Alanazi, A. A. A. (2023). Sleep hygiene practices and its impact on mental health and functional performance among adults in Tabuk City: A cross-sectional study. *Cureus.* https://doi.org/10.7759/cureus.36221

Aleman, R. S., Moncada, M., & Aryana, K. J. (2023). Leaky gut and the ingredients that help treat it: A review. *Molecules, 28*(2), 619. https://doi.org/10.3390/molecules28020619

Alharbi, S. H. (2024). Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. *Therapeutic Advances in Endocrinology and Metabolism, 15*, 20420188231222367. https://doi.org/10.1177/20420188231222367

Almdabgy, E. M., Qader, A., Binjahlan, A. A., Alshalawi, A. M., Albeladi, A., Alharbi, W. S., & Almehmadi, K. A. (2023). The impact of pulmonary rehabilitation on mental health and quality of life in patients with chronic obstructive pulmonary disease (COPD): A narrative review. *Cureus.* https://doi.org/10.7759/cureus.49230

Ambrosino, P., Nolano, M., Candia, C., Grassi, G., & Maniscalco, M. (2024). Addressing oxidative stress and endothelial dysfunction in chronic respiratory diseases: The role of exercise and multidisciplinary rehabilitation. *Antioxidants, 13*(12), 1543. https://doi.org/10.3390/antiox13121543

Anghel, L., Ciubară, A., Nechita, A., Nechita, L., Manole, C., Baroiu, L., Ciubară, A. B., & Mușat, C. L. (2023). Sleep disorders associated with neurodegenerative diseases. *Diagnostics, 13(18),* 2898. https://doi.org/10.3390/diagnostics13182898

Anghel, L., Ciubară, A., Patraș, D., & Ciubară, A. B. (2025). Chronic obstructive pulmonary disease and type 2 diabetes mellitus: Complex interactions and clinical implications. *Journal of Clinical Medicine, 14*(6), 1809. https://doi.org/10.3390/jcm14061809

Barnes, P. J. (2022). Oxidative stress in chronic obstructive pulmonary disease. *Antioxidants, 11*(5), 965. https://doi.org/10.3390/antiox11050965

Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023). Overcoming barriers to patient adherence: The case for developing innovative drug delivery systems. *Nature Reviews Drug Discovery, 22*(5), 387–409. https://doi.org/10.1038/s41573-023-00670-0

Basnet, J., Eissa, M. A., Yanes Cardozo, L. L., Romero, D. G., & Rezq, S. (2024). Impact of probiotics and prebiotics on gut microbiome and hormonal regulation. *Gastrointestinal Disorders, 6*(4), 801–815. https://doi.org/10.3390/gidisord6040056

Bazoukis, G., Stavrakis, S., & Armoundas, A. A. (2023). Vagus nerve stimulation and inflammation in cardiovascular disease: A state-of-the-art review. *Journal of the American Heart Association, 12*(19), e030539. https://doi.org/10.1161/JAHA.123.030539

Bellocchi, C., Carandina, A., Montinaro, B., Targetti, E., Furlan, L., Rodrigues, G. D., Tobaldini, E., & Montano, N. (2022). The interplay between autonomic nervous system and inflammation across systemic autoimmune diseases. *International Journal of Molecular Sciences, 23*(5), 2449. https://doi.org/10.3390/ijms23052449

Bezerra, F. S., Lanzetti, M., Nesi, R. T., Nagato, A. C., Silva, C. P. e, Kennedy-Feitosa, E., Melo, A. C., Cattani-Cavalieri, I., Porto, L. C., & Valenca, S. S. (2023). Oxidative stress and

inflammation in acute and chronic lung injuries. *Antioxidants, 12*(3), 548. https://doi.org/10.3390/antiox12030548

Bischof, G., Bischof, A., & Rumpf, H.-J. (2021). Motivational interviewing: An evidence-based approach for use in medical practice. *Deutsches Ärzteblatt International.* https://doi.org/10.3238/arztebl.m2021.0014

Bonilla-Jaime, H., Sánchez-Salcedo, J. A., Estevez-Cabrera, M. M., Molina-Jiménez, T., Cortes-Altamirano, J. L., & Alfaro-Rodríguez, A. (2022). Depression and pain: Use of antidepressants. *Current Neuropharmacology, 20*(2), 384–402. https://doi.org/10.2174/1570159X19666210609161447

Bouhamida, E., Morciano, G., Perrone, M., Kahsay, A. E., Della Sala, M., Wieckowski, M. R., Fiorica, F., Pinton, P., Giorgi, C., & Patergnani, S. (2022). The interplay of hypoxia signaling on mitochondrial dysfunction and inflammation in cardiovascular diseases and cancer: From molecular mechanisms to therapeutic approaches. *Biology, 11*(2), 300. https://doi.org/10.3390/biology11020300

Braam, A., Buljac-Samardzic, M., Hilders, C. G. J. M., & van Wijngaarden, J. D. H. (2022). Collaboration between physicians from different medical specialties in hospital settings: A systematic review. *Journal of Multidisciplinary Healthcare, 15*, 2277–2300. https://doi.org/10.2147/JMDH.S376927

Brandt, L., Liu, S., Heim, C., & Heinz, A. (2022). The effects of social isolation stress and discrimination on mental health. *Translational Psychiatry, 12*(1), 398. https://doi.org/10.1038/s41398-022-02178-4

Caturano, A., D'Angelo, M., Mormone, A., Russo, V., Mollica, M. P., Salvatore, T., Galiero, R., Rinaldi, L., Vetrano, E., Marfella, R., Monda, M., Giordano, A., & Sasso, F. C. (2023). Oxidative stress in type 2 diabetes: Impacts from pathogenesis to lifestyle modifications. *Current Issues in Molecular Biology, 45*(8), 6651–6666. https://doi.org/10.3390/cimb45080420

Cazzola, M., Hanania, N. A., Page, C. P., & Matera, M. G. (2023). Novel anti-inflammatory approaches to COPD. *International Journal of Chronic Obstructive Pulmonary Disease, 18*, 1333–1352. https://doi.org/10.2147/COPD.S419056

Cha, S.-R., Jang, J., Park, S.-M., Ryu, S. M., Cho, S.-J., & Yang, S.-R. (2023). Cigarette smoke-induced respiratory response: Insights into cellular processes and biomarkers. *Antioxidants, 12*(6), 1210. https://doi.org/10.3390/antiox12061210

Chen, Y., Xu, J., & Chen, Y. (2021). Regulation of neurotransmitters by the gut microbiota and effects on cognition in neurological disorders. *Nutrients, 13*(6), 2099. https://doi.org/10.3390/nu13062099

Choi, E.-H., Kim, M.-H., & Park, S.-J. (2024). Targeting mitochondrial dysfunction and reactive oxygen species for neurodegenerative disease treatment. *International Journal of Molecular Sciences, 25*(14), 7952. https://doi.org/10.3390/ijms25147952

Choi, J. Y., & Rhee, C. K. (2020). Diagnosis and treatment of early chronic obstructive lung disease (COPD). *Journal of Clinical Medicine, 9(11),* 3426. https://doi.org/10.3390/jcm9113426

Clemente-Suárez, V. J., Martín-Rodríguez, A., Redondo-Flórez, L., López-Mora, C., Yáñez-Sepúlveda, R., & Tornero-Aguilera, J. F. (2023). New insights and potential therapeutic interventions in metabolic diseases. *International Journal of Molecular Sciences, 24*(13), 10672. https://doi.org/10.3390/ijms241310672

Clímaco, D. C. S., Lustosa, T. C., Silva, M. V. F. P., Lins-Filho, O. L., Rodrigues, V. K., Oliveira-Neto, L. A. P., Feitosa, A. D. M., Queiroga Jr, F. J. P., Cabral, M. M., & Pedrosa, R. P. (2022). Sleep quality in COPD patients: Correlation with disease severity and health status. *Jornal Brasileiro de Pneumologia, e20210340.* https://doi.org/10.36416/1806-3756/e20210340

Coman, L.-I., Ianculescu, M., Paraschiv, E.-A., Alexandru, A., & Bădărău, I.-A. (2024). Smart Solutions for Diet-Related Disease Management: Connected Care, Remote Health Monitoring

Systems, and Integrated Insights for Advanced Evaluation. *Applied Sciences*, *14*(6), 2351. https://doi.org/10.3390/app14062351

Cross, A. J., Elliott, R. A., Petrie, K., Kuruvilla, L., & George, J. (2020). Interventions for improving medication-taking ability and adherence in older adults prescribed multiple medications. *Cochrane Database of Systematic Reviews, 2020*(5). https://doi.org/10.1002/14651858.CD012419.pub2

Dawi, J., Misakyan, Y., Affa, S., Kades, S., Narasimhan, A., Hajjar, F., Besser, M., Tumanyan, K., & Venketaraman, V. (2024). Oxidative stress, glutathione insufficiency, and inflammatory pathways in type 2 diabetes mellitus: Implications for therapeutic interventions. *Biomedicines, 13*(1), 18. https://doi.org/10.3390/biomedicines13010018

Del Toro-Barbosa, M., Hurtado-Romero, A., Garcia-Amezquita, L. E., & García-Cayuela, T. (2020). Psychobiotics: Mechanisms of action, evaluation methods, and effectiveness in applications with food products. *Nutrients, 12*(12), 3896. https://doi.org/10.3390/nu12123896

Deli, C. K., Fatouros, I. G., Poulios, A., Liakou, C. A., Draganidis, D., Papanikolaou, K., Rosvoglou, A., Gatsas, A., Georgakouli, K., Tsimeas, P., & Jamurtas, A. Z. (2024). Gut microbiota in the progression of type 2 diabetes and the potential role of exercise: A critical review. *Life, 14*(8), 1016. https://doi.org/10.3390/life14081016

Druszczynska, M., Sadowska, B., Kulesza, J., Gąsienica-Gliwa, N., Kulesza, E., & Fol, M. (2024). The intriguing connection between the gut and lung microbiomes. *Pathogens, 13*(11), 1005. https://doi.org/10.3390/pathogens13111005

Duan, R., Li, B., & Yang, T. (2023). Pharmacological therapy for stable chronic obstructive pulmonary disease. *Chronic Diseases and Translational Medicine, 9(2)*, 82–89. https://doi.org/10.1002/cdt3.65

Elendu, C., Babawale, E. A., Babarinde, F. O., Babatunde, O. D., Chukwu, C., Chiegboka, S. F., Shode, O. P., Ngozi-ibeh, J. K., Njoku, A., Ikokwu, M. N., Kaka, G. U., Hassan, J. I., Fatungase, O. O., Osifodunrin, T., Udoeze, C. A., & Ikeji, V. I. (2024). Neurological manifestations of lysosomal storage diseases. *Annals of Medicine & Surgery, 86*(11), 6619–6635. https://doi.org/10.1097/MS9.0000000000002611

Elgellaie, A., Thomas, S. J., Kaelle, J., Bartschi, J., & Larkin, T. (2023). Pro-inflammatory cytokines IL-1α, IL-6 and TNF-α in major depressive disorder: Sex-specific associations with psychological symptoms. *European Journal of Neuroscience, 57(11),* 1913–1928. https://doi.org/10.1111/ejn.15992

Esmaili, M., Farhud, D. D., Poushaneh, K., Baghdassarians, A., & Ashayeri, H. (2023). Executive functions and public health: A narrative review. *Iranian Journal of Public Health.* https://doi.org/10.18502/ijph.v52i8.13398

Ezeamii, V. C., Okobi, O. E., Wambai-Sani, H., Perera, G. S., Zaynieva, S., Okonkwo, C. C., Ohaiba, M. M., William-Enemali, P. C., Obodo, O. R., & Obiefuna, N. G. (2024). Revolutionizing healthcare: How telemedicine is improving patient outcomes and expanding access to care. *Cureus*. https://doi.org/10.7759/cureus.63881

Fanaridis, M., Bouloukaki, I., Stathakis, G., Steiropoulos, P., Tzanakis, N., Moniaki, V., Mavroudi, E., Tsiligianni, I., & Schiza, S. (2024). Prevalence and characteristics of patients with obstructive sleep apnea and chronic obstructive pulmonary disease: Overlap syndrome. *Life, 14*(5), 547. https://doi.org/10.3390/life14050547

Fornaro, R., Actis, G. C., Caviglia, G. P., Pitoni, D., & Ribaldone, D. G. (2022). Inflammatory bowel disease: Role of vagus nerve stimulation. *Journal of Clinical Medicine, 11*(19), 5690. https://doi.org/10.3390/jcm11195690

Goldstein, D. S. (2021). Stress and the "extended" autonomic system. *Autonomic Neuroscience, 236*, 102889. https://doi.org/10.1016/j.autneu.2021.102889

Hamrefors, V. (2023). The autonomous nervous system: A novel and potentially modifiable risk factor for chronic obstructive pulmonary disease in the population? *Annals of the American Thoracic Society, 20*(10), 1402–1403. https://doi.org/10.1513/AnnalsATS.202307-618ED

Herman, R., Kravos, N. A., Jensterle, M., Janež, A., & Dolžan, V. (2022). Metformin and insulin resistance: A review of the underlying mechanisms behind changes in GLUT4-mediated glucose transport. *International Journal of Molecular Sciences, 23*(3), 1264. https://doi.org/10.3390/ijms23031264

Hernández, B., Dyer, A. H., Finucane, C., Nipoti, B., Romero-Ortuno, R., Reilly, R., & Kenny, R. A. (2024). The impact of type 2 diabetes on peripheral and cerebral hemodynamic responses to active stand. *The Journals of Gerontology: Series A, 79*(5), glae073. https://doi.org/10.1093/gerona/glae073

Ho, D., Quake, S. R., McCabe, E. R. B., Chng, W. J., Chow, E. K., Ding, X., Gelb, B. D., Ginsburg, G. S., Hassenstab, J., Ho, C.-M., Mobley, W. C., Nolan, G. P., Rosen, S. T., Tan, P., Yen, Y., & Zarrinpar, A. (2020). Enabling technologies for personalized and precision medicine. *Trends in Biotechnology*, *38*(3), 225-236. https://doi.org/10.1016/j.tibtech.2019.12.021

Hrncir, T. (2022). Gut microbiota dysbiosis: Triggers, consequences, diagnostic and therapeutic options. *Microorganisms, 10*(3), 578. https://doi.org/10.3390/microorganisms10030578

Hughes, M. J., McGettrick, H. M., & Sapey, E. (2020). Shared mechanisms of multimorbidity in COPD, atherosclerosis, and type-2 diabetes: The neutrophil as a potential inflammatory target. *European Respiratory Review, 29(155),* 190102. https://doi.org/10.1183/16000617.0102-2019

Idlett-Ali, S. L., Salazar, C. A., Bell, M. S., Short, E. B., & Rowland, N. C. (2023). Neuromodulation for treatment-resistant depression: Functional network targets contributing to antidepressive outcomes. *Frontiers in Human Neuroscience, 17*, 1125074. https://doi.org/10.3389/fnhum.2023.1125074

Iheagwam, F. N., Joseph, A. J., Adedoyin, E. D., Iheagwam, O. T., & Ejoh, S. A. (2025). Mitochondrial dysfunction in diabetes: Shedding light on a widespread oversight. *Pathophysiology, 32*(1), 9. https://doi.org/10.3390/pathophysiology32010009

Iida, H., Yamaguchi, S., Goyagi, T., Sugiyama, Y., Taniguchi, C., Matsubara, T., Yamada, N., Yonekura, H., & Iida, M. (2021). Prevention of psychoactive substance use. *Archiv Euromedica, 11*(5), 59–61. https://doi.org/10.35630/2199-885X/2021/11/5.16

Johnson, K. B., Wei, W.-Q., Weeraratne, D., Frisse, M. E., Misulis, K., Rhee, K., Zhao, J. L., & Snowdon, J. L. (2021). Precision medicine, AI, and the future of personalized health care. *Clinical and Translational Science, 14*(1), 86–93. https://doi.org/10.1111/cts.12884

Joo, J. H., Bone, L., Forte, J., Kirley, E., Lynch, T., & Aboumatar, H. (2022). The benefits and challenges of established peer support programmes for patients, informal caregivers, and healthcare providers. *Family Practice, 39*(5), 903–912. https://doi.org/10.1093/fampra/cmac004

Kanaley, J. A., Colberg, S. R., Corcoran, M. H., Malin, S. K., Rodriguez, N. R., Crespo, C. J., Kirwan, J. P., & Zierath, J. R. (2022). Exercise/physical activity in individuals with type 2 diabetes: A consensus statement from the American College of Sports Medicine. *Medicine & Science in Sports & Exercise, 54*(2), 353–368. https://doi.org/10.1249/MSS.0000000000002800

Kandpal, M., Indari, O., Baral, B., Jakhmola, S., Tiwari, D., Bhandari, V., Pandey, R. K., Bala, K., Sonawane, A., & Jha, H. C. (2022). Dysbiosis of gut microbiota from the perspective of the gut–brain axis: Role in the provocation of neurological disorders. *Metabolites, 12*(11), 1064. https://doi.org/10.3390/metabo12111064

Karuga, F. F., Kaczmarski, P., Białasiewicz, P., Szmyd, B., Jaromirska, J., Grzybowski, F., Gebuza, P., Sochal, M., & Gabryelska, A. (2023). REM-OSA as a tool to understand both the architecture of sleep and pathogenesis of sleep apnea—Literature review. *Journal of Clinical Medicine, 12*(18), 5907. https://doi.org/10.3390/jcm12185907

Katkenov, N., Mukhatayev, Z., Kozhakhmetov, S., Sailybayeva, A., Bekbossynova, M., & Kushugulova, A. (2024). Systematic review on the role of IL-6 and IL-1β in cardiovascular diseases. *Journal of Cardiovascular Development and Disease, 11*(7), 206. https://doi.org/10.3390/jcdd11070206

Kayongo, A., Robertson, N. M., Siddharthan, T., Ntayi, M. L., Ndawula, J. C., Sande, O. J., Bagaya, B. S., Kirenga, B., Mayanja-Kizza, H., Joloba, M. L., Forslund, S. K., & Forslund, S. K. (2023). Airway microbiome-immune crosstalk in chronic obstructive pulmonary disease. *Frontiers in Immunology, 13*, 1085551. https://doi.org/10.3389/fimmu.2022.1085551

Kirkbride, J. B., Anglin, D. M., Colman, I., Dykxhoorn, J., Jones, P. B., Patalay, P., Pitman, A., Soneson, E., Steare, T., Wright, T., & Griffiths, S. L. (2024). The social determinants of mental health and disorder: Evidence, prevention, and recommendations. *World Psychiatry, 23*(1), 58–90. https://doi.org/10.1002/wps.21160

Kouba, B. R., Borba, L. de A., Souza, P. B. de, Gil-Mohapel, J., & Rodrigues, A. L. S. (2024). Role of inflammatory mechanisms in major depressive disorder: From etiology to potential pharmacological targets. *Cells, 13*(5), 423. https://doi.org/10.3390/cells13050423

Kurowska, A., Ziemichód, W., Herbet, M., & Piątkowska-Chmiel, I. (2023). The Role of Diet as a Modulator of the Inflammatory Process in the Neurological Diseases. *Nutrients*, *15*(6), 1436. https://doi.org/10.3390/nu15061436

Lau, R. S., Boesen, M. E., Richer, L., & Hill, M. D. (2024). Siloed mentality, health system suboptimization and the healthcare symphony: A Canadian perspective. *Health Research Policy and Systems, 22*(1), 87. https://doi.org/10.1186/s12961-024-01168-w

Lea, S., Higham, A., Beech, A., & Singh, D. (2023). How inhaled corticosteroids target inflammation in COPD. *European Respiratory Review, 32*(170), 230084. https://doi.org/10.1183/16000617.0084-2023

Lee, T. C., Shah, N. U., Haack, A., & Baxter, S. L. (2020). Clinical implementation of predictive models embedded within electronic health record systems: A systematic review. *Informatics, 7*(3), 25. https://doi.org/10.3390/informatics7030025

Liang, Y., Ruan, W., Jiang, Y., Smalling, R., Yuan, X., & Eltzschig, H. K. (2023). Interplay of hypoxia-inducible factors and oxygen therapy in cardiovascular medicine. *Nature Reviews Cardiology, 20*(11), 723–737. https://doi.org/10.1038/s41569-023-00886-y

Miravitlles, M. (2023). Improving outcomes of chronic obstructive pulmonary disease through the treatment of comorbidities: One step beyond. *American Journal of Respiratory and Critical Care Medicine, 208*(10), 1017–1019. https://doi.org/10.1164/rccm.202309-1546ED

Lin, C. H., Cheng, S. L., Chen, C. Z., Chen, C. H., Lin, S. H., & Wang, H. C. (2023). Current progress of COPD early detection: Key points and novel strategies. *International Journal of Chronic Obstructive Pulmonary Disease, 18*, 1511–1524. https://doi.org/10.2147/COPD.S413969

Liu, F.-J., Wu, J., Gong, L.-J., Yang, H.-S., & Chen, H. (2024). Non-invasive vagus nerve stimulation in anti-inflammatory therapy: Mechanistic insights and future perspectives. *Frontiers in Neuroscience, 18*, 1490300. https://doi.org/10.3389/fnins.2024.1490300

Liu, M., Li, Y., Yin, D., Wang, Y., Fu, T., Zhu, Z., Zheng, C., & Huang, K. (2023). COPD Assessment Test as a screening tool for anxiety and depression in stable COPD patients: A feasibility study. *COPD: Journal of Chronic Obstructive Pulmonary Disease, 20*(1), 144–152. https://doi.org/10.1080/15412555.2023.2174843

Lohrasbi, F., Alavi, M., Akbari, M., & Maghsoudi, J. (2023). Promoting psychosocial health of family caregivers of patients with chronic mental disorders: A review of challenges and strategies. *Chonnam Medical Journal, 59*(1), 31. https://doi.org/10.4068/cmj.2023.59.1.31

Lu, S., Zhao, Q., Guan, Y., Sun, Z., Li, W., Guo, S., & Zhang, A. (2024). The communication mechanism of the gut-brain axis and its effect on central nervous system diseases: A systematic review. *Biomedicine & Pharmacotherapy, 178*, 117207. https://doi.org/10.1016/j.biopha.2024.117207

Luo, C., Sanger, N., Singh, N., Pattrick, K., Shams, I., Shahid, H., Hoang, P., Schmidt, J., Lee, J., Haber, S., Puckering, M., Buchanan, N., Lee, P., Nga, K., Sun, S., Kheyson, S., Chunge, D. C.-Y., Sanger, S., Thabane, L., & Samaan, Z. (2020). A comparison of electronically-delivered and face-to-face cognitive behavioural therapies in depressive

disorders: A systematic review and meta-analysis. *eClinicalMedicine, 24*, 100442. https://doi.org/10.1016/j.eclinm.2020.100442

MacKillop, J., Agabio, R., Feldstein Ewing, S. W., Heilig, M., Kelly, J. F., Leggio, L., Lingford-Hughes, A., Palmer, A. A., Parry, C. D., Ray, L., & Rehm, J. (2022). Hazardous drinking and alcohol use disorders. *Nature Reviews Disease Primers, 8*(1), 80. https://doi.org/10.1038/s41572-022-00406-1

Marculescu, A. D., Gavat, C.-C., Nechita, A., Topor, G., Vasilescu, L. V., Debita, M., Axente, E. R., Trinca, C. L., & Anghel, L. (2019). Investigation of linearity, detection limit (LD) and quantitation limit (LQ) of active substance from pharmaceutical tablets. *Revista de Chimie*, 70(1), 259–262. https://doi.org/10.37358/RC.19.1.6895

Mariniello, D. F., D'Agnano, V., Cennamo, D., Conte, S., Quarcio, G., Notizia, L., Pagliaro, R., Schiattarella, A., Salvi, R., Bianco, A., & Perrotta, F. (2024). Comorbidities in COPD: Current and future treatment challenges. *Journal of Clinical Medicine, 13*(3), 743. https://doi.org/10.3390/jcm13030743

Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., Silva, I., Magalhães, P., Schmidt, S., & Vale, N. (2024). Advancing precision medicine: A review of innovative in silico approaches for drug development, clinical pharmacology, and personalized healthcare. *Pharmaceutics, 16*(3), 332. https://doi.org/10.3390/pharmaceutics16030332

Mechlińska, A., Wiglusz, M. S., Słupski, J., Włodarczyk, A., & Cubała, W. J. (2023). Exploring the relationship between mood disorders and coexisting health conditions: The focus on nutraceuticals. *Brain Sciences, 13*(9), 1262. https://doi.org/10.3390/brainsci13091262

Menear, M., Girard, A., Dugas, M., Gervais, M., Gilbert, M., & Gagnon, M.-P. (2022). Personalized care planning and shared decision making in collaborative care programs for depression and anxiety disorders: A systematic review. *PLOS ONE, 17*(6), e0268649. https://doi.org/10.1371/journal.pone.0268649

Mikulska, J., Juszczyk, G., Gawrońska-Grzywacz, M., & Herbet, M. (2021). HPA axis in the pathomechanism of depression and schizophrenia: New therapeutic strategies based on its participation. *Brain Sciences, 11*(10), 1298. https://doi.org/10.3390/brainsci11101298

Miravitlles, M. (2023). Improving outcomes of chronic obstructive pulmonary disease through the treatment of comorbidities: One step beyond. *American Journal of Respiratory and Critical Care Medicine, 208*(10), 1017–1019. https://doi.org/10.1164/rccm.202309-1546ED

Montori, V. M., Ruissen, M. M., Hargraves, I. G., Brito, J. P., & Kunneman, M. (2023). Shared decision-making as a method of care. *BMJ Evidence-Based Medicine, 28(4)*, 213–217. https://doi.org/10.1136/bmjebm-2022-112068

Moretta, P., Cavallo, N. D., Candia, C., Lanzillo, A., Marcuccio, G., Santangelo, G., Marcuccio, L., Ambrosino, P., & Maniscalco, M. (2024). Psychiatric disorders in patients with chronic obstructive pulmonary disease: Clinical significance and treatment strategies. *Journal of Clinical Medicine, 13*(21), 6418. https://doi.org/10.3390/jcm13216418

Mostafavi Abdolmaleky, H., & Zhou, J.-R. (2024). Gut microbiota dysbiosis, oxidative stress, inflammation, and epigenetic alterations in metabolic diseases. *Antioxidants, 13*(8), 985. https://doi.org/10.3390/antiox13080985

Mu, F., Rusip, G., & Florenly, F. (2024). Gut microbiota and autoimmune diseases: Insights from Mendelian randomization. *FASEB BioAdvances, 6*(11), 467–476. https://doi.org/10.1096/fba.2024-00037

Mumtaz, H., Riaz, M. H., Wajid, H., Saqib, M., Zeeshan, M. H., Khan, S. E., Chauhan, Y. R., Sohail, H., & Vohra, L. I. (2023). Current challenges and potential solutions to the use of digital health technologies in evidence generation: A narrative review. *Frontiers in Digital Health, 5*, 1203945. https://doi.org/10.3389/fdgth.2023.1203945

Nambi, G., Alghadier, M., Vellaiyan, A., Ebrahim, E. E., Aldhafian, O. R., Mohamed, S. H. P., Albalawi, H. F. A., Chevidikunnan, M. F., Khan, F., Mani, P., Saleh, A. K., & Alshahrani, N. N. (2023). Role of tele-physical therapy training on glycemic control, pulmonary function,

physical fitness, and health-related quality of life in patients with type 2 diabetes mellitus (T2DM) following COVID-19 infection—A randomized controlled trial. *Healthcare, 11(12)*, 1791. https://doi.org/10.3390/healthcare11121791

Neale, C. D., Christensen, P. E., Dall, C., Ulrik, C. S., Godtfredsen, N., & Hansen, H.(2022). Sleep quality and self-reported symptoms of anxiety and depression are associated with physical activity in patients with severe COPD. *International Journal of Environmental Research and Public Health, 19*(24), 16804. https://doi.org/10.3390/ijerph192416804

Ojeda, J., Ávila, A., & Vidal, P. M. (2021). Gut microbiota interaction with the central nervous system throughout life. *Journal of Clinical Medicine, 10*(6), 1299. https://doi.org/10.3390/jcm10061299

Oudat, Q., & Okour, A. (2025). The role of probiotics in modulating gut microbiota and metabolic health for weight management: A mini review. *Acta Microbiologica Hellenica, 70*(1), 5. https://doi.org/10.3390/amh70010005

Øvretveit, J., Hansson, J., & Brommels, M. (2010). An integrated health and social care organisation in Sweden: Creation and structure of a unique local public health and social care system. *Health Policy, 97*(2–3), 113–121. https://doi.org/10.1016/j.healthpol.2010.05.012

P, S., & Vellapandian, C. (2024). Hypothalamic-pituitary-adrenal (HPA) axis: Unveiling the potential mechanisms involved in stress-induced Alzheimer's disease and depression. *Cureus.* https://doi.org/10.7759/cureus.67595

Palamarchuk, I. S., & Vaillancourt, T. (2021). Mental resilience and coping with stress: A comprehensive, multi-level model of cognitive processing, decision making, and behavior. *Frontiers in Behavioral Neuroscience, 15*, 719674. https://doi.org/10.3389/fnbeh.2021.719674

Panahi, S., Rathi, N., Hurley, J., Sundrud, J., Lucero, M., Kamimura, A. (2022). Patient adherence to health care provider recommendations and medication among free clinic patients. *Journal of Patient Experience, 9*, 23743735221077523. https://doi.org/10.1177/23743735221077523

Park, S. S., Perez Perez, J. L., Perez Gandara, B., Agudelo, C. W., Rodriguez Ortega, R., Ahmed, H., Garcia-Arcos, I., McCarthy, C., & Geraghty, P. (2022). Mechanisms linking COPD to type 1 and 2 diabetes mellitus: Is there a relationship between diabetes and COPD? *Medicina, 58*(8), 1030. https://doi.org/10.3390/medicina58081030

Perrone, P., & D'Angelo, S. (2025). Gut microbiota modulation through Mediterranean diet foods: Implications for human health. *Nutrients, 17*(6), 948. https://doi.org/10.3390/nu17060948

Poot, C. C., Meijer, E., Kruis, A. L., Smidt, N., Chavannes, N. H., & Honkoop, P. J. (2021). Integrated disease management interventions for patients with chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews, 2021*(9). https://doi.org/10.1002/14651858.CD009437.pub3

Posluns, K., & Gall, T. L. (2020). Dear mental health practitioners, take care of yourselves: A literature review on self-care. *International Journal for the Advancement of Counselling, 42*(1), 1–20. https://doi.org/10.1007/s10447-019-09382-w

Potts, L. C., & Henderson, C. (2020). Moderation by socioeconomic status of the relationship between familiarity with mental illness and stigma outcomes. *SSM - Population Health, 11*, 100611. https://doi.org/10.1016/j.ssmph.2020.100611

Qannita, R. A., Alalami, A. I., Harb, A. A., Aleidi, S. M., Taneera, J., Abu-Gharbieh, E., El-Huneidi, W., Saleh, M. A., Alzoubi, K. H., Semreen, M. H., Hudaib, M., & Bustanji, Y. (2024). Targeting hypoxia-inducible factor-1 (HIF-1) in cancer: Emerging therapeutic strategies and pathway regulation. *Pharmaceuticals, 17*(2), 195. https://doi.org/10.3390/ph17020195

Rahelić, V., Perković, T., Romić, L., Perković, P., Klobučar, S., Pavić, E., & Rahelić, D. (2024). The role of behavioral factors on chronic diseases—Practice and knowledge gaps. *Healthcare, 12*(24), 2520. https://doi.org/10.3390/healthcare12242520

Rahi, M. S., Thilagar, B., Balaji, S., Prabhakaran, S. Y., Mudgal, M., Rajoo, S., Yella, P. R., Satija, P., Zagorulko, A., & Gunasekaran, K. (2023). The impact of anxiety and depression in chronic

obstructive pulmonary disease. *Advances in Respiratory Medicine, 91*(2), 123–134. https://doi.org/10.3390/arm91020011

Rau, S., Gregg, A., Yaceczko, S., & Limketkai, B.(2024). Prebiotics and probiotics for gastrointestinal disorders. *Nutrients, 16*(6), 778. https://doi.org/10.3390/nu16060778

Rauf, A., Badoni, H., Abu-Izneid, T., Olatunde, A., Rahman, M. M., Painuli, S., Semwal, P., Wilairatana, P., & Mubarak, M. S. (2022). Neuroinflammatory markers: Key indicators in the pathology of neurodegenerative diseases. *Molecules, 27*(10), 3194. https://doi.org/10.3390/molecules27103194

Recio Iglesia, J., Díez-Manglano, J., López García, F., Díaz Peromingo, J. A., Almagro, P., & Varela Aguilar, J. M. (2020). Management of the COPD patient with comorbidities: An experts recommendation document. *International Journal of Chronic Obstructive Pulmonary Disease, 15*, 1015–1037. https://doi.org/10.2147/COPD.S242009

Religioni, U., Barrios-Rodríguez, R., Requena, P., Borowska, M., & Ostrowski, J. (2025). Enhancing therapy adherence: Impact on clinical outcomes, healthcare costs, and patient quality of life. *Medicina, 61(1)*, 153. https://doi.org/10.3390/medicina61010153

Rethorst, C. D., Trombello, J. M., Chen, P., Carmody, T. J., Lazalde, A., & Trivedi, M. H. (2023). Adaption of tele-behavioral activation to increase physical activity in depression: Protocol for iterative development and evaluation. *Contemporary Clinical Trials Communications, 33*, 101103. https://doi.org/10.1016/j.conctc.2023.101103

Reynolds, C. F. 3rd, Jeste, D. V., Sachdev, P. S., & Blazer, D. G. (2022). Mental health care for older adults: Recent advances and new directions in clinical practice and research. *World Psychiatry, 21*(3), 336–363. https://doi.org/10.1002/wps.20996

Robertson, N. M., Centner, C. S., & Siddharthan, T. (2024). Integrating artificial intelligence in the diagnosis of COPD globally: A way forward. *Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, 11*(1), 114–120. https://doi.org/10.15326/jcopdf.2023.0449

Schrijver, J., Lenferink, A., Brusse-Keizer, M., Zwerink, M., van der Valk, P. D. L. P. M., van der Palen, J., & Effing, T. W. (2022). Self-management interventions for people with chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews, 2023(3).* https://doi.org/10.1002/14651858.CD002990.pub4

Schupack, D. A., Mars, R. A. T., Voelker, D. H., Abeykoon, J. P., & Kashyap, P. C. (2022). The promise of the gut microbiome as part of individualized treatment strategies. *Nature Reviews Gastroenterology & Hepatology, 19*(1), 7–25. https://doi.org/10.1038/s41575-021-00499-1

Scott, A. J., Webb, T. L., Martyn-St James, M., Rowse, G., & Weich, S. (2021). Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials. *Sleep Medicine Reviews, 60,* 101556. https://doi.org/10.1016/j.smrv.2021.101556

Selzler, A.-M., Ellerton, C., Ellerton, L., Habash, R., Nekolaichuk, E., Goldstein, R., & Brooks, D. (2023). The relationship between physical activity, depression, and anxiety in people with COPD: A systematic review and meta-analyses. *COPD: Journal of Chronic Obstructive Pulmonary Disease, 20(1),* 167–177. https://doi.org/10.1080/15412555.2023.2200826

Semrau, M., Gronholm, P. C., Eaton, J., Maulik, P. K., Ayele, B., Bakolis, I., Mendon, G. B., Bhattarai, K., Brohan, E., Cherian, A. V., Daniel, M., Girma, E., Gurung, D., Hailemariam, A., Hanlon, C., Healey, A., Kallakuri, S., Li, J., Loganathan, S., Ma, N., Ma, Y., Metsahel, A., Ouali, U., Yaziji, N., Zgueb, Y., Zhang, W., Zhang, X., Thornicroft, G., & Votruba, N. (2023). Reducing stigma and improving access to care for people with mental health conditions in the community: Protocol for a multi-site feasibility intervention study (Indigo-Local). *Research Square*. https://doi.org/10.21203/rs.3.rs-3237562/v1

Sharifi-Rad, M., Anil Kumar, N. V., Zucca, P., Varoni, E. M., Dini, L., Panzarini, E., Rajkovic, J., Tsouh Fokou, P. V., Azzini, E., Peluso, I., Mishra, A. P., Nigam, M., El Rayess, Y., El Beyrouthy, M., Polito, L., Iriti, M., Martins, N., Martorell, M., Docea, A. O., Setzer, W. N., Calina, D., Cho, W. C., & Sharifi-Rad, J. (2020). Lifestyle, oxidative stress, and antioxidants:

Back and forth in the pathophysiology of chronic diseases. *Frontiers in Physiology, 11*, 694. https://doi.org/10.3389/fphys.2020.00694

Siraj, R. A. (2023). Comorbid cognitive impairment in chronic obstructive pulmonary disease (COPD): Current understanding, risk factors, implications for clinical practice, and suggested interventions. *Medicina, 59*(4), 732. https://doi.org/10.3390/medicina59040732

Søvold, L. E., Naslund, J. A., Kousoulis, A. A., Saxena, S., Qoronfleh, M. W., Grobler, C., & Münter, L. (2021). Prioritizing the mental health and well-being of healthcare workers: An urgent global public health priority. *Frontiers in Public Health, 9*, 679397. https://doi.org/10.3389/fpubh.2021.679397

Stein, D. J., Shoptaw, S. J., Vigo, D. V., Lund, C., Cuijpers, P., Bantjes, J., Sartorius, N., & Maj, M. (2022). Psychiatric diagnosis and treatment in the 21st century: Paradigm shifts versus incremental integration. *World Psychiatry, 21*(3), 393–414. https://doi.org/10.1002/wps.20998

Syeda, U. A., Battillo, D., Visaria, A., & Malin, S. K. (2023). The importance of exercise for glycemic control in type 2 diabetes. *American Journal of Medicine Open, 9*, 100031. https://doi.org/10.1016/j.ajmo.2023.100031

Tarar, P., Bandi, V. V., Sarwar, H., Maged, R., Sinha, M., Koneru, H. M., & Malasevskaia, I. (2024). Exploring the interrelationship between diabetes mellitus and chronic lung diseases: A comprehensive review. *Cureus.* https://doi.org/10.7759/cureus.69617

Taylor, G. M. J., Lindson, N., Farley, A., Leinberger-Jabari, A., Sawyer, K., te Water Naudé, R., Theodoulou, A., King, N., Burke, C., & Aveyard, P. (2021). Smoking cessation for improving mental health. *Cochrane Database of Systematic Reviews, 2021(3).* https://doi.org/10.1002/14651858.CD013522.pub2

Vainauskienė, V., & Vaitkienė, R. (2021). Enablers of Patient Knowledge Empowerment for Self-Management of Chronic Disease: An Integrative Review. International Journal of Environmental Research and Public Health, 18(5), 2247. https://doi.org/10.3390/ijerph18052247

Vargas-Uricoechea, H., Castellanos-Pinedo, A., Urrego-Noguera, K., Vargas-Sierra, H. D., Pinzón-Fernández, M. V., Barceló-Martínez, E., & Ramírez-Giraldo, A. F. (2024). Mindfulness-based interventions and the hypothalamic–pituitary–adrenal axis: A systematic review. *Neurology International, 16*(6), 1552–1584. https://doi.org/10.3390/neurolint16060115

Volpato, E., Toniolo, S., Pagnini, F., & Banfi, P. (2021). The relationship between anxiety, depression, and treatment adherence in chronic obstructive pulmonary disease: A systematic review. *International Journal of Chronic Obstructive Pulmonary Disease, 16*, 2001–2021. https://doi.org/10.2147/COPD.S313841

Wagenaar, C. A., van de Put, M., Bisschops, M., Walrabenstein, W., de Jonge, C. S., Herrema, H., & van Schaardenburg, D. (2021). The effect of dietary interventions on chronic inflammatory diseases in relation to the microbiome: A systematic review. *Nutrients, 13*(9), 3208. https://doi.org/10.3390/nu13093208

Wang, B., Li, Z.-L., Zhang, Y.-L., Wen, Y., Gao, Y.-M., & Liu, B.-C. (2022). Hypoxia and chronic kidney disease. *eBioMedicine, 77*, 103942. https://doi.org/10.1016/j.ebiom.2022.103942

Wang, R. C., & Wang, Z. (2023). Precision medicine: Disease subtyping and tailored treatment. *Cancers, 15*(15), 3837. https://doi.org/10.3390/cancers15153837

Weinberg, R. S., Segev, O., Dor, S., & Raz, I. (2024). Overview of oxidative stress and inflammation in diabetes. *Journal of Diabetes, 16*(10), e70014. https://doi.org/10.1111/1753-0407.70014

Williams, M. T., Johnston, K. N., & Paquet, C. (2020). Cognitive behavioral therapy for people with chronic obstructive pulmonary disease: Rapid review. *International Journal of Chronic Obstructive Pulmonary Disease, 15*, 903–919. https://doi.org/10.2147/COPD.S178049

Xiong, R.-G., Li, J., Cheng, J., Zhou, D.-D., Wu, S.-X., Huang, S.-Y., Saimaiti, A., Yang, Z.-J., Gan, R.-Y., & Li, H.-B. (2023). The role of gut microbiota in anxiety, depression, and other mental

disorders as well as the protective effects of dietary components. *Nutrients, 15*(14), 3258. https://doi.org/10.3390/nu15143258

Yaribeygi, H., Maleki, M., Butler, A. E., Jamialahmadi, T., & Sahebkar, A. (2022). Molecular mechanisms linking stress and insulin resistance. *EXCLI Journal, 21*, Doc317. https://doi.org/10.17179/EXCLI2021-4382

Yu, X., Pu, H., & Voss, M. (2024). Overview of anti-inflammatory diets and their promising effects on non-communicable diseases. *British Journal of Nutrition, 132*(7), 898–918. https://doi.org/10.1017/S0007114524001405

Zandi, H., Amirinejhad, A., Azizifar, A., Aibod, S., Veisani, Y., & Mohamadian, F. (2021). The effectiveness of mindfulness training on coping with stress, exam anxiety, and happiness to promote health. *Journal of Education and Health Promotion, 10*(1), 177. https://doi.org/10.4103/jehp.jehp_616_20

Zhang, D., Lee, E. K. P., Mak, E. C. W., Ho, C. Y., & Wong, S. Y. S. (2021). Mindfulness-based interventions: An overall review. *British Medical Bulletin, 138(1)*, 41–57. https://doi.org/10.1093/bmb/ldab005